FTC Clears Amgen’s $27.8B Horizon Therapeutics Buyout.
The Federal Trade Commission (FTC) has approved the $27.8 billion acquisition of Horizon Therapeutics by pharmaceutical giant Amgen. This decision comes after the FTC had initially filed a lawsuit in May, aiming to block the acquisition, citing concerns that it could lead to a “stifling of competition” within the pharmaceutical industry.
However, the FTC has temporarily suspended the lawsuit this week, allowing for consideration of a potential settlement in the case.
The news of the FTC’s clearance positively impacted the stock market, as shares of Horizon Therapeutics experienced a nearly 3% rise in premarket trading on Friday. Meanwhile, Amgen’s stock saw a slight increase as well.
Amgen‘s interest in acquiring Horizon Therapeutics dates back to December 2022, when the company announced its intent to purchase the latter. The primary motivation behind this acquisition was to access Horizon’s portfolio of rare disease assets, including the highly regarded thyroid eye disease therapy, Tepezza.
However, this acquisition quickly attracted significant attention from regulatory and political circles due to concerns about potential antitrust issues. In its lawsuit, the FTC argued that the deal could strengthen the monopoly positions of Horizon’s rapidly growing medications, particularly Tepezza and Krystexxa, a gout medicine.
One critical concern the FTC raised was Amgen’s ability to leverage its existing drug portfolio to gain an advantage over potential competitors.
The agency believed that, with this acquisition, Amgen could offer rebates on its current drugs, pressuring insurers and pharmacy benefit managers to prioritize Horizon’s products through a “cross-market bundling.”
Cross-market bundling refers to offering discounts or incentives on one product to influence the adoption or preference of another product in a different market or category. In this case, Amgen could use its existing drugs to exert pressure and create favorable conditions for the success of Horizon’s Tepezza and Krystexxa in the market.
The FTC’s lawsuit was grounded in the belief that such a strategy would ultimately reduce competition in the pharmaceutical industry by limiting choices for consumers and healthcare providers. Monopoly-like conditions created by the acquisition could lead to higher prices and fewer options for patients needing these medications.
However, the decision to temporarily suspend the lawsuit suggests that the FTC is open to exploring alternative resolutions to address its concerns while allowing the acquisition to proceed.
Settlement negotiations could involve specific conditions or commitments from Amgen to mitigate the potential antitrust issues associated with the deal.
The pharmaceutical industry has been under increasing scrutiny recently for concerns related to pricing, competition, and access to essential medications.
Regulatory bodies like the FTC play a crucial role in ensuring that mergers and acquisitions within the industry do not harm competition or the interests of consumers.
As the situation unfolds, monitoring any developments in the negotiations between Amgen and the FTC will be necessary. The outcome of this case will not only impact the fate of the Horizon Therapeutics acquisition but also have broader implications for competition within the pharmaceutical sector.
It serves as a reminder of the ongoing challenges and complexities in regulating mergers and acquisitions in industries critical to public health and well-being.
In conclusion, the FTC’s decision to allow Amgen’s $27.8 billion acquisition of Horizon Therapeutics to move forward, albeit with a temporarily suspended lawsuit, marks a significant development in the pharmaceutical industry.
The concerns raised by the FTC about potential antitrust issues and the impact on competition underscore the importance of regulatory oversight in ensuring fair and competitive markets in the healthcare sector.
The outcome of this case will be closely watched by industry stakeholders, policymakers, and the public, as it could have far-reaching implications for access to and pricing of essential medications.
